578 results on '"Del-Bel, Elaine"'
Search Results
52. Extrapyramidal Side Effects with Chronic Atypical Antipsychotic Can Be Predicted by Labeling Pattern of FosB and phosphoThr 34 -DARPP-32 in Nucleus Accumbens.
53. Rescue of Dopamine Neurons from Iron-Dependent Ferroptosis by Doxycycline and Demeclocycline and Their Non-Antibiotic Derivatives
54. Decreased glial reactivity could be involved in the antipsychotic-like effect of cannabidiol
55. Disturbance of sensorimotor filtering in the 6-OHDA rodent model of Parkinson's disease
56. The Presence of the Neuronal Nitric Oxide Synthase Isoform in the Intervertebral Disk
57. Are cyclooxygenase-2 and nitric oxide involved in the dyskinesia of Parkinson's disease induced by L-DOPA?
58. Doxycycline attenuates l-DOPA-induced dyskinesia through an anti-inflammatory effect in a hemiparkinsonian mouse model
59. Exploiting the therapeutic potential of ready-to-use drugs: Repurposing antibiotics against amyloid aggregation in neurodegenerative diseases
60. Clinical Developments in Antimicrobial Nanomedicine
61. List of Contributors
62. Oral nanomedicine and the emergent process of clinical translation
63. List of Contributors
64. Can anti-inflammatory agents improve L-DOPA-induced dyskinesia in parkinsonian animals?
65. Nanomedicine to Overcome Current Parkinson’s Treatment Liabilities: A Systematic Review
66. Antidyskinetic Effect of 7-Nitroindazole and Sodium Nitroprusside Associated with Amantadine in a Rat Model of Parkinson’s Disease
67. Doxycycline Suppresses Microglial Activation by Inhibiting the p38 MAPK and NF-kB Signaling Pathways
68. CX3CR1 Disruption Differentially Influences Dopaminergic Neuron Degeneration in Parkinsonian Mice Depending on the Neurotoxin and Route of Administration
69. Signaling Mechanisms in the Nitric Oxide Donor- and Amphetamine-Induced Dopamine Release in Mesencephalic Primary Cultured Neurons
70. Cannabidiol attenuates catalepsy induced by distinct pharmacological mechanisms via 5-HT1A receptor activation in mice
71. Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders
72. Doxycycline to treat levodopa-induced dyskinesias in Parkinson's disease: a preliminary study.
73. DOXYCYCLINE TO TREAT LEVODOPA-INDUCED DYSKINESIAS IN PARKINSON’S DISEASE: A PROOF-OF-CONCEPT STUDY
74. Levodopa-induced dyskinesias in Parkinson’s disease increase cerebrospinal fluid nitric oxide metabolites’ levels
75. Metabolic Profile in Plasma AND CSF of LEVODOPA-induced Dyskinesia in Parkinson’s Disease: Focus on Neuroinflammation
76. Cannabidiol attenuates haloperidol-induced catalepsy and c-Fos protein expression in the dorsolateral striatum via 5-HT1A receptors in mice
77. Critical role of nitric oxide in the modulation of prepulse inhibition in Swiss mice
78. Evaluation of Nigrostriatal Neurodegeneration and Neuroinflammation Following Repeated Intranasal 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) Administration in Mice, an Experimental Model of Parkinson’s Disease
79. Counteraction by Nitric Oxide Synthase Inhibitor of Neurochemical Alterations of Dopaminergic System in 6-OHDA-Lesioned Rats Under l-DOPA Treatment
80. Upregulation of FosB/ΔFosB in limbic circuits after tooth exodontia-induced occlusal instability in an experimental model of unpredictable chronic stress
81. Cannabidiol has therapeutic potential for myofascial pain in female and male parkinsonian rats
82. Effects of prolonged neuronal nitric oxide synthase inhibition on the development and expression of l-DOPA-induced dyskinesia in 6-OHDA-lesioned rats
83. The Chemically-Modified Tetracycline COL-3 and Its Parent Compound Doxycycline Prevent Microglial Inflammatory Responses by Reducing Glucose-Mediated Oxidative Stress
84. Does the country matter? Research and career of a Brazilian Fellow Member
85. Cannabidiol-treated Rats Exhibited Higher Motor Score After Cryogenic Spinal Cord Injury
86. New Strategies in Neuroprotection and Neurorepair
87. CANNABIDIOL AND CANNABIGEROL LIMIT L-DOPA-INDUCED DYSKINESIA WHEN GIVEN SEPARATELY OR IN COMBINATION TO HEMIPARKINSONIAN RATS
88. NEUROPROTECTION OF DOPAMINE NEURONS BY OXYTETRACYCLINE AND ITS NON-ANTIBIOTIC DERIVATIVE DOT IN A CULTURE MODEL OF IRON-DEPENDENT FERROPTOSIS
89. SEX-RELATED DIFFERENCES IN THE ANTINOCICEPTIVE EFFECT OF CANNABIDIOL IN A RODENT MODEL OF TRIGEMINAL NEURALGIA.
90. CANNABIDIOL HAS THERAPEUTIC POTENTIAL FOR MYOFASCIAL PAIN IN FEMALE AND MALE PARKINSONIAN RATS
91. COULD THE COMBINATION OF TWO NON-PSYCHOTROPIC CANNABINOIDS COUNTERACT HALOPERIDOL CATALEPSY? EFFECTIVENESS OF CANNABIDIOL ASSOCIATED WITH CANNABIGEROL
92. ATTENUATION OF HALOPERIDOL-INDUCED VACUOUS CHEWING MOVEMENTS BY CANNABIGEROL TREATMENT IN MICE
93. BRAINSTEM MODULATES PARKINSONISM-INDUCED OROFACIAL SENSORIMOTOR DYSFUNCTIONS
94. PARTICIPATION OF TRPV1 RECEPTORS AND EFFICACY OF THE ANTINOCICEPTIVE EFFECTS OF CANNABIDIOL AND A FLUORINATED DERIVATIVE IN A CHRONIC PAIN ANIMAL MODEL OF TRIGEMINAL NEURALGIA
95. THE ROLE OF AN INTERACTION OF ENDOCANNABINOID, ENDOVANILLOID AND NITRERGIC SYSTEMS IN THE ANTIDYSKINETIC EFFECT OF CANNABIDIOL IN A RODENT MODEL OF PARKINSON’S DISEASE
96. THE NON-ANTIBIOTIC TETRACYCLINES DDMC AND DDOX REDUCE PAIN-RELATED RESPONSES IN MICE SUBJECTED TO THE FORMALIN TEST
97. Doxycycline and its derivative, COL-3, decrease dyskinesia induced by l-DOPA in hemiparkinsonian rats.
98. Mice with genetic deletion of the heparin-binding growth factor midkine exhibit early preclinical features of Parkinson’s disease
99. Influence of decortication of the recipient graft bed on graft integration and tissue neoformation in the graft-recipient bed interface
100. The antibiotic doxycycline mimics the NGF signaling in PC12 cells: A relevant mechanism for neuroprotection
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.